Pancreatic Cancer Research

ResearcherGeorgetown UniversityNo recent work listed

Jimmy J. Hwang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5104103465. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper

Papers 8

  1. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy. Co-author DOI 10.1016/j.amjsurg.2020.10.030↗
  2. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  3. Advances in borderline resectable pancreatic adenocarcinoma. Last author PMID 32628656↗
  4. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000620↗
  5. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001354↗
  6. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic c… Co-author DOI 10.3892/ol.2016.4101↗
  7. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-015-2855-z↗
  8. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Last author PMID 25276262↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David A. Iannitti · 2 shared papers, 2020–2021 · strength 0.27
  2. Aiwu Ruth He · 4 shared papers, 2014–2020 · strength 0.26
  3. John Lindsay Marshall · 4 shared papers, 2014–2020 · strength 0.26
  4. Michael Jon Pishvaian · 4 shared papers, 2014–2020 · strength 0.26
  5. Andrew H. Ko · 2 shared papers, 2019 · strength 0.24
  6. Celso L. Diaz · 2 shared papers, 2019 · strength 0.24
  7. Margaret A. Tempero · 2 shared papers, 2019 · strength 0.24
  8. Louis M. Weiner · 3 shared papers, 2015–2020 · strength 0.21
  9. Benjamin Adam Weinberg · 2 shared papers, 2014–2020 · strength 0.15
  10. Deepak Vadehra · 1 shared paper, 2020 · strength 0.13
  11. John B. Martinie · 1 shared paper, 2021 · strength 0.13
  12. Lee Mayer Ocuin · 1 shared paper, 2021 · strength 0.13
  13. Michael David Watson · 1 shared paper, 2021 · strength 0.13
  14. Erin H. Baker · 1 shared paper, 2021 · strength 0.13
  15. Dionisios V. Vrochides · 1 shared paper, 2021 · strength 0.13
  16. Pelin Cinar · 1 shared paper, 2019 · strength 0.12
  17. Claire Johns · 1 shared paper, 2019 · strength 0.11
  18. Jonathan Robert Brody · 1 shared paper, 2020 · strength 0.11
  19. Brandon George Smaglo · 1 shared paper, 2020 · strength 0.11
  20. Zheng Wu · 2 shared papers, 2015–2016 · strength 0.10
  21. Xue‐Fei Tian · 1 shared paper, 2016 · strength 0.05
  22. Anton Wellstein · 1 shared paper, 2016 · strength 0.05
  23. Christina Sing-Ying Wu · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.